Robert Williams
Roughly one in three people diagnosed with cancer will face a chemotherapy bill that exceeds $100,000 over the course of their treatment. That number stopped me cold the first time I saw it, because the follow-up question matters just as much: how much of that does Medicare actually cover? The answer is more complicated than most people expect, and I’ll be honest, I got it wrong myself for years before I really dug into the details.
Most seniors assume Medicare covers chemotherapy the same way it covers a doctor’s visit. It doesn’t. Where your chemo is administered, whether it’s a pill or an infusion, and which part of Medicare you’re enrolled in can swing your out-of-pocket costs by tens of thousands of dollars in a single year. That’s not a small planning detail. That’s the difference between keeping your savings intact and watching them evaporate.
What surprised me most when I researched this deeply is how few oncology patients fully understand their cost exposure before treatment starts. A 2023 survey by the Kaiser Family Foundation found that nearly 40% of Medicare beneficiaries with cancer reported difficulty affording their care, even though they had coverage. Coverage isn’t the same thing as affordability.
- Medicare Part B covers IV chemotherapy at 80% after the deductible; you owe 20% with no cap.
- Oral chemo drugs fall under Part D, where costs vary dramatically by plan and formulary tier.
- Without a Medigap (Medicare Supplement) policy, the 20% Part B coinsurance has no annual limit.
- The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year starting in 2025.
- A single chemotherapy drug like bevacizumab (Avastin) can cost Medicare over $5,000 per infusion.
How Medicare Splits Chemo Into Two Very Different Worlds
Here’s the structural thing that trips people up. Medicare doesn’t treat all chemotherapy as one category. It splits it based on how the drug is delivered.
Intravenous (IV) chemotherapy administered in a hospital outpatient department or a doctor’s office is covered under Medicare Part B (Medical Insurance). You’ll pay 20% of the Medicare-approved amount after your annual Part B deductible, which sits at $240 in 2026. No annual out-of-pocket maximum. That 20% can get brutal fast when you’re receiving drugs like carboplatin or rituximab, which Medicare reimburses at rates that can hit $3,000 to $8,000 per session or more depending on the drug and dosage.
Oral chemotherapy, the kind you take as a pill or capsule at home, is a different story. Those drugs are covered under Medicare Part D (Prescription Drug Coverage). The specific cost depends entirely on which plan you’re enrolled in and which tier the drug falls on in that plan’s formulary (the approved drug list). Some oral chemo drugs, like capecitabine (Xeloda) or temozolomide (Temodar), can land on specialty tiers with coinsurance rates of 25% to 33%. Before 2025, there was no cap on how much you could spend under Part D. Starting in 2025, thanks to the Inflation Reduction Act, the annual out-of-pocket maximum under Part D is $2,000. That’s a genuinely significant protection that didn’t exist just a few years ago.
The bifurcation matters because your coverage strategy has to address both parts. I’ve talked with seniors who had excellent Medigap coverage for their infusions but were blindsided by the cost of a take-home chemo pill that their Part D plan placed on the highest specialty tier.
The Real Numbers: What You Might Actually Pay
Helpful resource: Medicare and You 2024 Official Handbook (Amazon) is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)
Let me put some concrete figures on this. These are based on current Medicare reimbursement data and cost structures as of August 2026.
| Scenario | Medicare Coverage | Your Potential Cost |
|---|---|---|
| IV chemo, no Medigap, no MOOP cap | Part B pays 80% | 20% of total, unlimited exposure |
| IV chemo with Medigap Plan G | Part B pays 80%, Medigap covers 20% | $0 coinsurance after Part B deductible |
| Oral chemo under Part D (specialty tier) | Varies by plan | Up to $2,000/year out-of-pocket (2026 cap) |
| Chemo in a hospital inpatient setting | Part A (Hospital Insurance) | $1,676 inpatient deductible per benefit period in 2026 |
| IV chemo at an ambulatory surgery center | Part B pays 80% | 20% coinsurance, same as outpatient |
The inpatient versus outpatient distinction deserves a brief callout: most chemotherapy today is delivered in outpatient settings, which means Part B, not Part A. But if you’re hospitalized and receive chemo during that stay, Part A applies. The billing department may not always make this obvious.
A few worked examples show how the numbers play out in real life:
Example 1: A 71-year-old woman in Ohio receiving monthly IV infusions of pertuzumab and trastuzumab for HER2-positive breast cancer. Medicare reimburses roughly $12,000 per session. Without Medigap, her 20% share is about $2,400 per session, or $28,800 over 12 months. With a Medigap Plan G (typically $120 to $200 per month in premiums), her cost drops to $240 for the year (just the Part B deductible). The math is overwhelmingly in favor of Medigap.
Example 2: A 68-year-old man in Texas taking lenalidomide (Revlimid) orally for multiple myeloma. This drug historically cost patients several thousand dollars per month under Part D. Under the 2026 Part D $2,000 annual out-of-pocket cap, his maximum exposure is now $2,000 for the year regardless of the drug’s actual price. That’s a meaningful improvement, though still real money.
Example 3: A 74-year-old woman enrolled in a Medicare Advantage (Part C) plan receiving carboplatin infusions. Her plan has a $7,000 annual out-of-pocket maximum. She hits it by month four. For the remainder of the year, her covered chemo costs are $0. Whether Medicare Advantage saves or costs more depends heavily on the specific plan.
Medigap: The Piece Most People Wait Too Long to Get
Medicare Part B Premium Cost - Shocking! What is IRMAA? · Medicare on Video - Medicare Specialist on YouTube
I’ll be honest about something. The single most common mistake I see seniors make is waiting until after a diagnosis to think about Medigap. By then, in most states, insurers can deny you coverage or charge higher premiums based on your health history. The guaranteed issue window, when you can’t be turned down, is typically the six months immediately following your enrollment in Part B.
Medigap Plan G is the one I’d look at most carefully for cancer coverage. It covers the Part B coinsurance (that unlimited 20%), the Part A deductible, and several other gaps. Plan N is another option, slightly cheaper, but it retains some copays. Plan F, which covered the Part B deductible too, is no longer available to people who became Medicare-eligible after January 1, 2020.
The Centers for Medicare & Medicaid Services publishes standardized plan comparison information, and Medicare.gov has a tool where you can compare Medigap plans available in your ZIP code. I’d use it. The premium differences between insurers for the same plan letter can be $50 to $100 a month, and they’re covering identical benefits by law.
Medicare Advantage and Chemotherapy: Proceed Carefully
Medicare Advantage plans (Part C) can look attractive on paper, often $0 monthly premium and extra benefits like dental and vision. What surprises many people facing a cancer diagnosis inside an Advantage plan is the network restriction. Your oncologist, the cancer center you want, may not be in-network. And switching back to Original Medicare outside of specific enrollment windows is not always straightforward.
That said, Advantage plans do have annual out-of-pocket maximums, which Original Medicare lacks for Part B. For some people in some plans, this can actually provide meaningful cost protection. The research here is genuinely mixed. A 2022 JAMA Oncology study found that cancer patients on Medicare Advantage had similar survival outcomes to those on Original Medicare but reported more access barriers. I don’t have clean numbers on how costs compare across all cancer types and all Advantage plans, so I won’t pretend I do.
What I’d suggest: if you’re enrolled in Medicare Advantage and get a serious cancer diagnosis, immediately check whether your preferred oncologist and cancer center are in-network. If they’re not, check your enrollment window options.
Sources
- Kaiser Family Foundation (KFF): Medicare and cancer affordability survey data, 2023
- Centers for Medicare & Medicaid Services (CMS): 2026 Part B deductible, Part D out-of-pocket cap, and Medicare reimbursement data
- JAMA Oncology: 2022 study comparing cancer outcomes and access in Medicare Advantage vs. Original Medicare
- Medicare.gov: Medigap plan comparison tool and Part D drug cost resources
- Inflation Reduction Act (Public Law 117-169): Provisions capping Part D out-of-pocket costs at $2,000 beginning 2025
Photo: Ivan S via Pexels
This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.
Recommended Resources
Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.
- Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
- Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.
